|
|
|
Insider
Information: |
Wysenski Nancy |
Relationship: |
Director |
City: |
Chatsworth |
State: |
CA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
6 |
|
Direct
Shares |
93,398 |
|
Indirect Shares
|
11,242 |
|
|
Direct
Value |
$17,223,738 |
|
|
Indirect Value
|
$275,429 |
|
|
Total
Shares |
104,640 |
|
|
Total
Value |
$17,499,167 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
1
|
0
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
1
|
0
|
|
|
|
Gain/Loss Ratio : |
-1.0
|
0.0
|
Percentage
Gain/Loss : |
-12.4%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Endo Health Solutions Inc |
ENDP |
Chief Operating Officer |
2009-02-26 |
13,054 |
2008-02-21 |
0 |
Premium* |
|
Vertex Pharmaceuticals Inc |
VRTX |
EVP, Chief Commercial ... |
2012-05-14 |
32,232 |
2009-12-09 |
0 |
Premium* |
|
Inovio Biomedical Corp |
INO |
Director |
2016-05-08 |
5,000 |
2016-05-08 |
0 |
Premium* |
|
Dova Pharmaceuticals, Inc. |
DOVA |
Director |
2019-11-12 |
0 |
2019-02-05 |
0 |
Premium* |
|
Alkermes Plc |
ALKS |
Director |
2023-07-07 |
20,356 |
2023-07-07 |
11,242 |
Premium* |
|
Cytokinetics Inc |
CYTK |
Director |
2024-05-15 |
22,756 |
2021-01-04 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
42 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 2 of 2
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
ALKS |
Alkermes Plc |
Director |
|
2023-07-07 |
4 |
D |
$29.88 |
$42,728 |
D/D |
(1,430) |
20,356 |
0 |
- |
|
ALKS |
Alkermes Plc |
Director |
|
2023-05-09 |
4 |
OE |
$31.13 |
$1,284,113 |
D/D |
41,250 |
57,079 |
0 |
- |
|
ALKS |
Alkermes Plc |
Director |
|
2023-05-09 |
4 |
AS |
$31.24 |
$1,288,786 |
D/D |
(41,250) |
15,829 |
0 |
% |
|
ALKS |
Alkermes Plc |
Director |
|
2019-03-14 |
4 |
B |
$33.06 |
$14,712 |
I/I |
445 |
4,302 |
2.1 |
- |
|
ALKS |
Alkermes Plc |
Director |
|
2019-02-21 |
4 |
B |
$33.09 |
$127,628 |
I/I |
3,857 |
3,857 |
2.1 |
- |
|
CYTK |
Cytokinetics Inc |
Director |
|
2023-07-03 |
4 |
A |
$33.36 |
$6,238 |
D/D |
187 |
16,858 |
0 |
- |
|
CYTK |
Cytokinetics Inc |
Director |
|
2021-10-01 |
4 |
A |
$36.74 |
$5,621 |
D/D |
153 |
5,881 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Commercial Officer |
|
2012-01-19 |
4 |
AS |
$37.00 |
$223,554 |
D/D |
(6,042) |
21,893 |
0 |
- |
|
CYTK |
Cytokinetics Inc |
Director |
|
2023-04-03 |
4 |
A |
$37.71 |
$5,619 |
D/D |
149 |
11,671 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Commercial Officer |
|
2012-05-14 |
4 |
OE |
$37.86 |
$7,134,605 |
D/D |
180,000 |
212,232 |
0 |
- |
|
CYTK |
Cytokinetics Inc |
Director |
|
2022-04-01 |
4 |
A |
$38.38 |
$5,603 |
D/D |
146 |
6,149 |
0 |
- |
|
CYTK |
Cytokinetics Inc |
Director |
|
2022-07-01 |
4 |
A |
$41.00 |
$5,617 |
D/D |
137 |
11,286 |
0 |
- |
|
CYTK |
Cytokinetics Inc |
Director |
|
2023-01-03 |
4 |
A |
$44.35 |
$5,588 |
D/D |
126 |
11,522 |
0 |
- |
|
CYTK |
Cytokinetics Inc |
Director |
|
2022-01-03 |
4 |
A |
$46.00 |
$5,612 |
D/D |
122 |
6,003 |
0 |
- |
|
CYTK |
Cytokinetics Inc |
Director |
|
2022-10-03 |
4 |
A |
$51.11 |
$5,622 |
D/D |
110 |
11,396 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Chief Commercial Officer |
|
2012-05-14 |
4 |
AS |
$64.27 |
$11,568,872 |
D/D |
(180,000) |
32,232 |
0 |
- |
|
CYTK |
Cytokinetics Inc |
Director |
|
2024-01-02 |
4 |
A |
$84.12 |
$6,225 |
D/D |
74 |
17,156 |
0 |
- |
|
42 Records found
|
|
Page 2 of 2 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|